3Billion Inc is a Korea-based company principally engaged in the provision of genetic testing services. The Company is principally engaged in the provision of rare genetic disease diagnostic testing services. The Company is also engaged in the research and development of technology that automatically reads the pathogenicity of numerous genetic variants found in the genome.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
18/26/18	₩4,770.00	+10.67%	11,18,000
17/26/17	₩4,310.00	+6.16%	8,83,981
16/26/16	₩4,060.00	-3.79%	1,46,484
15/26/15	₩4,220.00	+2.80%	1,09,600
14/26/14	₩4,105.00	-4.53%	1,33,985

End-of-day quote Korea S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. 18/09/2026			5-day change	1st Jan Change
4,770.00 ^KRW	+10.67%		+10.93%	-73.83%

01/06	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
13/05	3billion, Inc. announced that it has received KRW 29.9999999 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI

Market Cap	15TCr 11Cr 9.53Cr 9Cr 8.17Cr 15Cr 1.05TCr 15Cr 107.76Cr 42Cr 533.04Cr 41Cr 40Cr 1.72TCr	P/E 2025	-107x	P/E 2026 *	-
Enterprise Value	13Cr 97.1T 84.67T 79.95T 72.6T 1L 93.17L 1L 10L 4L 47.37L 4L 4L 1.52Cr	EV / Sales 2025	49x	EV / Sales 2026 *	-
Free-Float	75.33%	Yield 2025 *	-	Yield 2026 *	-

01/06	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
13/05	3billion, Inc. announced that it has received KRW 29.9999999 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI
23/04	3billion, Inc. announced that it expects to receive KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd. and other investors.	CI
09/04	3Billion Inc wins 955 million won order	RE
23/03	3billion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
18/25/18	3Billion Inc Wins 655 Million Won Order	RE

1 day	+10.67%
1 week	+10.93%
Current month	-7.92%
1 month	-17.47%
3 months	-29.02%
6 months	-67.84%
Current year	-73.83%

3billion, Inc. Share Price

Stocks

A394800

KR7394800007

Biotechnology & Medical Research

Valuation: 3billion, Inc.

Chart: 3billion, Inc.

Latest news: 3billion, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: 3billion, Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	4,020	5,120
1 month	4,020	5,530
Current year	4,020	18,690
1 year	4,020	20,100
3 years	3,025	20,100
5 years	3,025	20,100
10 years	3,025	20,100

Manager	Title	Age	Since
Chang-Won Geum CEO	Chief Executive Officer	45	10/10/2016
Soon-Il Park DFI	Director of Finance/CFO	46	01/10/2020
Jeong-Seol Lee CTO	Chief Tech/Sci/R&D Officer	46	01/08/2018

Director	Title	Age	Since
Chang-Won Geum BRD	Director/Board Member	45	10/10/2016
Se-Hwan Kim BRD	Director/Board Member	44	10/10/2016
Ki-Hyeon Kang BRD	Director/Board Member	44	18/11/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/04/25	Soon-Il Park	Others	Chief Financial Officer	44,000	0.1387%
07/03/25	Soon-Il Park	Exercice	Chief Financial Officer	40,000	0.1262%
07/03/25	Ki-hyun Kang	Exercice		10,000	0.0316%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
3BILLION, INC.	+10.67%	+10.93%	-35.54%	-	11Cr
IOVANCE BIOTHERAPEUTICS, INC.	+2.30%	+19.19%	+400.00%	+95.24%	464.3Cr
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+0.21%	+18.22%	+114.15%	+452.32%	456.6Cr
VERACYTE, INC.	-1.91%	-2.63%	+16.67%	+70.57%	319.91Cr
CAREDX, INC.	-0.83%	+7.10%	+268.95%	+586.61%	278.49Cr
BGI GENOMICS CO., LTD.	+6.41%	+10.68%	-21.68%	-25.15%	227.38Cr
FREENOME, INC.	+10.59%	+13.36%	+53.68%	-	183.84Cr
SEEGENE, INC.	+0.30%	+7.13%	+27.07%	+55.76%	110.86Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	-4.13%	+6.74%	+158.15%	-30.37%	103.85Cr
CURIOX BIOSYSTEMS CO., LTD	-3.88%	-4.48%	-19.56%	+45.09%	57Cr
Average	+1.97%	+8.84%	+96.19%	+156.26%	221.29Cr
Weighted average by Cap.	+1.46%	+10.84%	+154.06%	+216.31%

	2025	2026 *
Net sales	1.08TCr 77.74L 67.79L 64.01L 58.12L 1.09Cr 75Cr 1.09Cr 7.67Cr 2.96Cr 38Cr 2.92Cr 2.86Cr 122.03Cr	-
Net income	-580Cr -41.75L -36.41L -34.38L -31.22L -58.48L -40Cr -58.73L -4.12Cr -1.59Cr -20Cr -1.57Cr -1.53Cr -66Cr	-
Net Debt	-1.69TCr -1.22Cr -1.06Cr -1Cr -90.95L -1.7Cr -116.73Cr -1.71Cr -12Cr -4.63Cr -59Cr -4.57Cr -4.47Cr -190.95Cr	-